Menu
GWAS Study

Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.

Hurkmans EGE, Klumpers MJ, Dello Russo C et al.

36699085 PubMed ID
GWAS Study Type
899 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HE
Hurkmans EGE
KM
Klumpers MJ
DR
Dello Russo C
DW
De Witte W
GH
Guchelaar HJ
GH
Gelderblom H
CA
Cleton-Jansen AM
VS
Vermeulen SH
KS
Kaal S
VD
van der Graaf WTA
FU
Flucke U
GC
Gidding CEM
SH
Schreuder HWB
DB
de Bont ESJM
CH
Caron HN
GG
Gattuso G
SE
Schiavello E
TM
Terenziani M
MM
Massimino M
MG
McCowage G
NS
Nagabushan S
LA
Limaye A
RV
Rose V
CD
Catchpoole D
JA
Jorgensen AL
BC
Barton C
DL
Delaney L
HD
Hawcutt DB
PM
Pirmohamed M
PB
Pizer B
CM
Coenen MJH
TL
Te Loo DMWM
Chapter II

Abstract

Summary of the research findings

Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value <10-5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5-2.7), p-value 5.0 × 10-7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.

302 European ancestry cases, 207 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

899
Total Participants
GWAS
Study Type
Yes
Replicated
168 European ancestry cases, 222 European ancestry controls
Replication Participants
European
Ancestry
Netherlands, Italy, U.K., Australia
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.